This pathway appears to play a role in adapting cancer cells to chronic inflammation conditions with high NF-κB activation and Th2 cytokine levels, that induce an immunosuppressive microenvironment in the tumor [51], as reported for GBM [59]. The gene discussed is NFKB1; the disease is glioblastoma.